ELVN · Enliven Therapeutics Inc.
AI read · Good for ELVN
The AI's read
William Blair started coverage and flagged ELVN-001 Phase 1b results showing 61% overall MMR and 48% MMR at 24 weeks at 80 mg QD. Those outcomes plus claimed activity against Scemblix resistance point to real clinical differentiation. The stock barely budged and RSI is mid-40s, so the market has not ripped this in yet. Enliven also reported $895.2M cash runway into 2030, which reduces near-term financing risk. We lean bullish because idiosyncratic clinical upside plus a long runway create asymmetric return potential. Keep size small. This is an early, binary biotech bet.